小剂量干扰素联合胸腺肽α1序贯治疗耐核苷类药物的失代偿期乙肝肝硬化临床研究  

Clinical study of low dose interferon with Thymosin α1 in the treatment of patients with decompensated HBV-related cirrhosis

作　　者：张国顺[1] 尚华[2] 张文缓 王娜[1] 魏丽[1] 张莹[1] 

机构地区：[1]河北联合大学附属医院消化内科,河北唐山063000 [2]唐山市传染病医院 [3]武警河北总队医院唐山分院

出　　处：《现代预防医学》2013年第7期1399-1400,F0003,共3页Modern Preventive Medicine

摘　　要：目的观察耐核苷类药物的失代偿期乙肝肝炎肝硬化患者抗病毒、调节免疫治疗的疗效和安全性。方法将67例耐核苷类药物的失代偿期乙肝肝炎肝硬化患者随机分为3组,A组21例,继续给予原核苷类药物治疗;B组23例,给予原核苷类药物治疗+干扰素;C组23例,给予原核苷类药物治疗+干扰素+胸腺肽α1;3组患者治疗观察48周。结果 A组患者治疗后肝功能指标及血清肝纤维化指标较前略有好转,与治疗前比较差异无统计学意义(P﹥0.05)。B组患者肝功能指标好转,治疗24周时与治疗前比较差异无统计学意义(P﹥0.05)。血清肝纤维化指标治疗前比较差异无统计学意义(P﹥0.05)。治疗48周时肝功能指标和血清肝纤维化指标与治疗前比较差异有统计学意义(P﹤0.01),C组患者肝功能指标好转和血清肝纤维化指标无论24周还是48周下降程度均优于A组和B组(P﹤0.01)。结论耐核苷类药物的失代偿期乙型肝炎肝硬化患者应用小剂量干扰素抗病毒治疗,能抑制乙肝病毒复制,同时应用胸腺肽α1调节免疫治疗可有效的改善患者肝功能及肝纤维化。OBJECTIVE To investigate the efficacy and safety of low dose interferon and Thymosin α1 anti -virus treatment on liver cirrhosis resulting from hepatitis B. METHODS Sixty-seven patients with liver cirrhosis resulting from hepatitis B were randomly divided into A group 21 cases （Nucleoside drug therapy）, B group 23 cases （Nucleoside drug ＋ interferon） and C group 23 cases （Nucleoside drug ＋ interferon and Thymosin α1）. Observed these patients for 48 weeks. RESULTS Being treated for forty-eight weeks.the liver function and hepatic fibrosis in group A were not significantly improved comparing with those before treatment. The liver function and hepatic fibrosis in group B were significantly improved comparing with those before treatment （P﹤0.01）. The hepatic fibrosis in group C were significantly ameliorated.The serum albumin in group C was obviously raised comparing with that in group A and B （P﹤0.01）. CONCLUSION Interferon can rapidly and effectively inhibit the replication of HBV in patients with decompensated hepatitis B and cirrhosis and improve the liver function.If combined with Thymosin α1, the therapeutic effect on hepatic fibrosis and the serum albumin elevation would be more manifested.

关 键 词：干扰素 胸腺肽Α1 核苷类药物 肝炎 乙型 肝硬化 失代偿期 

分 类 号：R657.31[医药卫生—外科学]